Stock Report

All about this stock under one free report Last Updated: 13-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Madrigal Pharmaceuticals (MDGL) Peer Comparison

Stock Card factsheet share-fund-plan-icon

$534.49

up-down-arrow $1.37 (0.26%)

As on 11-Sep-2026 16:00EDT

Market cap

info icon

$12,349 Mln

Revenue (TTM)

info icon

$1,284 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

23.5

Div. Yield

info icon

0 %

Edit peer-selector-edit
Madrigal Pharmaceuticals (MDGL) Ascendis Pharma A/S - ADR Medpace Holdings (MEDP) Exelixis (EXEL) Halozyme Therapeutics (HALO)
Market cap ($ Mln)
 12,349 17,335 16,399 13,906 12,167
Revenue ($ Mln)
 1,284 1,054 2,782 2,436 1,664
Net Profit ($ Mln)
 -325.10 755.85 491.50 860.62 413.60
Net Margin (%)
 -25.32 71.69 17.67 35.33 24.86
RoE (%)
 -57.72 -- 110.09 42.98 430.03
Price to Earnings
 -- 20.24 34.46 17.65 31.44
Price-To-Book
 23.52 10.29 37.52 7.54 84.60

Income Statement ($ Mln)

Madrigal Pharmaceuticals (MDGL) Ascendis Pharma A/S - ADR Medpace Holdings (MEDP) Exelixis (EXEL) Halozyme Therapeutics (HALO)
Operating Revenue arrow
1,283.94 1,054.37 2,782.29 2,435.92 1,663.74
Cost of Revenue arrow
109.42 103.47 1,982.07 85.67 363.07
Gross Profit arrow
902.26 588.53 760.62 2,236.43 1,091.18
Operating Expenses arrow
1,497.13 841.45 216.81 1,378.74 356.18
Operating Profit (EBIT) arrow
-322.62 109.45 583.40 971.51 944.49
Other Income arrow
0.00 0.00 0.00 0.00 0.00
Profit before Tax arrow
-325.10 101.11 598.92 1,035.47 583.34
Provision for Tax arrow
0.00 -654.74 107.42 174.84 169.74
Profit after Tax (Net Income) arrow
-325.10 755.85 491.50 860.62 413.60
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Consolidated Profit arrow
0.00 0.00 0.00 0.00 0.00

Liabilities ($ Mln)

Madrigal Pharmaceuticals (MDGL) Ascendis Pharma A/S - ADR Medpace Holdings (MEDP) Exelixis (EXEL) Halozyme Therapeutics (HALO)
Shareholder's Funds arrow
523.72 1,435.90 433.86 1,843.76 143.54
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Non-Current Liabilities arrow
346.72 384.48 187.89 288.55 2,089.43
Current Liabilities arrow
374.20 464.70 1,435.43 361.93 344.44
Total Liabilities arrow
1,259.59 1,302.02 1,975.47 2,844.42 2,525.32

Assets ($ Mln)

Madrigal Pharmaceuticals (MDGL) Ascendis Pharma A/S - ADR Medpace Holdings (MEDP) Exelixis (EXEL) Halozyme Therapeutics (HALO)
Non-Current Assets arrow
45.47 895.24 1,006.90 1,243.41 1,644.38
Current Assets arrow
1,199.18 1,389.84 1,050.29 1,250.82 933.02
Total Assets arrow
1,259.59 1,302.02 1,975.47 2,844.42 2,525.32
Total Debt* arrow
347.75 449.89 120.10 165.93 2,146.65
Net Current Assets arrow
824.98 925.52 -385.14 888.90 588.59

Cashflow ($ Mln)

Madrigal Pharmaceuticals (MDGL) Ascendis Pharma A/S - ADR Medpace Holdings (MEDP) Exelixis (EXEL) Halozyme Therapeutics (HALO)
Cash From Operating Activities arrow
-189.55 51.77 713.22 884.27 651.56
Cash Flow from Investing Activities arrow
32.32 -8.15 -31.14 350.44 -545.81
Cash from Financing Activities arrow
255.98 34.89 -860.39 -969.59 -85.17
Net Cash Inflow / Outflow arrow
-- -- -- -- --

Ratios

Profitability Ratios

 Madrigal Pharmaceuticals (MDGL) Ascendis Pharma A/S - ADR Medpace Holdings (MEDP) Exelixis (EXEL) Halozyme Therapeutics (HALO)
ROCE (%) arrow
-31.49 -30.01 53.56 32.82 15.61
ROE (%) arrow
-57.72 163.18 110.09 42.98 430.03
ROA (%) arrow
-22.97 31.68 15.64 29.32 16.19
EBIT Margin (%) arrow
-18.97 5.73 21.13 31.04 36.28
Net Margin (%) arrow
-25.32 71.69 17.67 35.33 24.86
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Madrigal Pharmaceuticals (MDGL) Ascendis Pharma A/S - ADR Medpace Holdings (MEDP) Exelixis (EXEL) Halozyme Therapeutics (HALO)
Revenue Growth (%) arrow
149.04 114.85 24.67 9.23 41.15
EBIT Growth (%) arrow
9.16 136.39 18.70 -3.99 -14.99
Net Profit Growth (%) arrow
-15.32 378.76 17.50 42.89 -25.78
EPS Growth (%) arrow
-0.64 353.27 26.84 50.42 -23.48
Book Value Growth (%) arrow
-42.66 816.12 164.02 -0.70 -55.81

Valuation Ratios

 Madrigal Pharmaceuticals (MDGL) Ascendis Pharma A/S - ADR Medpace Holdings (MEDP) Exelixis (EXEL) Halozyme Therapeutics (HALO)
Price / Earnings arrow
-45.32 -59.76 36.06 15.79 24.99
Price / Book Value arrow
23.52 10.29 37.52 7.54 84.60
Dividend Yield (%) arrow
0.00 0.00 0.00 0.00 0.00
EV/EBITDA arrow
-39.23 225.15 26.82 12.52 19.84
Market Cap ($ Cr) arrow
-- -- -- -- --

Solvency Ratios

 Madrigal Pharmaceuticals (MDGL) Ascendis Pharma A/S - ADR Medpace Holdings (MEDP) Exelixis (EXEL) Halozyme Therapeutics (HALO)
Debt to Equity arrow
0.65 0.27 0.00 0.00 13.50
Short term debt to equity ratio arrow
0.00 0.05 0.00 0.00 1.46
Current Ratio arrow
3.20 2.99 0.73 3.46 2.71
Quick Ratio arrow
2.94 2.32 0.73 3.38 2.31
Interest Coverage arrow
-9.32 1.62 -- -- 29.73

Operating Efficiency Ratios

 Madrigal Pharmaceuticals (MDGL) Ascendis Pharma A/S - ADR Medpace Holdings (MEDP) Exelixis (EXEL) Halozyme Therapeutics (HALO)
Debtors to sales (%) arrow
14.98 21.25 15.88 13.74 27.40
Asset Turnover arrow
0.91 0.44 0.89 0.83 0.65
Receivable days arrow
35.88 85.52 50.42 43.48 98.04
Inventory Days arrow
354.23 1,056.70 -- 96.17 190.34
Payable days arrow
300.79 331.01 6.26 147.97 18.62
Cash Conversion Cycle arrow
89.33 811.21 -- -8.32 269.75
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...